Form EFFECT ImmunoCellular Therapeut
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | August 15, 2016 |
Accession Number: | 0001628280-16-018872 | ||||||
Submission Type: | POS AM | ||||||
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HMN FINANCIAL, INC. ANNOUNCES FIRST QUARTER RESULTS
- U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
- Glow Announces Late Filing of Financial Statements
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!